Trust Signals
- Written by the FormBlends Medical Team, drawing on FDA prescribing information, peer-reviewed pharmacology, and published clinical trials in aplastic anemia and HIV wasting populations.
- No product is sold on this page. No affiliate commission influences the analysis.
- Every claim is labeled by evidence quality. Speculative claims are marked as such.
- Limitations and failure modes are disclosed, not buried.
- Updated: 2026-05-29.
Key Takeaways
- Oxymetholone (Anadrol-50) has an FDA-approved oral form; no injectable oxymetholone product has ever been approved by any major regulatory agency.
- The molecule's 17-alpha alkylation is the primary driver of hepatotoxicity, not first-pass metabolism, so injecting does not eliminate liver risk.
- The elimination half-life of oxymetholone is reported at roughly 8 to 9 hours regardless of route; injectable depot effects alter absorption, not elimination.
- No human RCT has directly compared injectable versus oral oxymetholone for anabolic outcomes or hepatic safety, so most claims about injectable superiority are pharmacokinetic theory only.
- Injectable oxymetholone sold in gray markets is unregulated, unverified for concentration, and carries contamination risk on top of all risks shared with the oral form.
Direct Answer: Which Is Safer or More Effective?
For the anadrol injectable vs oral question, the honest answer is: the evidence does not favor either route in the way most sources claim. Both deliver the same hepatotoxic, androgenic molecule. The injection-is-safer-on-the-liver argument is plausible in theory but unproven in any human trial. No approved injectable form exists, which adds significant real-world risk from unregulated supply.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is oxymetholone and why does route matter at all?
- Evidence ledger: what the data actually supports
- How does anadrol work and what do the specific numbers show?
- Why does 17-alpha alkylation cause liver damage regardless of route?
- What most pages get wrong about injectable anadrol
- Honest head-to-head: injectable vs oral vs oxandrolone
- Half-life, depot effects, and plasma curves explained
- Operational and label literacy: how to read what you actually have
- FAQ
- Sources
- Footer Disclaimers
What Is Oxymetholone and Why Does Route Matter at All?
Oxymetholone is a synthetic anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT), with a 2-hydroxymethylene modification and 17-alpha methyl group. The FDA approved Anadrol-50 in 1961 for treating anemias caused by deficient red blood cell production, including aplastic anemia. It is classified as a Schedule III controlled substance under the Controlled Substances Act.
Route of administration matters pharmacologically because it affects:
- Peak portal vein concentration (highest after oral dosing, lower after injection)
- Time to peak plasma concentration (Tmax)
- Absorption smoothness and potential depot effects with oil-based injectable preparations
Route does NOT change the molecular structure, its binding affinity at androgen receptors, or the presence of the 17-alpha methyl group that drives hepatotoxicity. This distinction is critical and routinely omitted in popular sources.
Evidence Ledger: What the Data Actually Supports
| Claim | Best Evidence Type | Direction | Confidence |
|---|---|---|---|
| Oral oxymetholone increases red blood cell mass in aplastic anemia | Multiple human RCTs and controlled trials (e.g., Besa 1990, multi-center aplastic anemia studies) | Positive effect confirmed | High |
| Oral oxymetholone elevates ALT/AST dose-dependently | Human clinical trials (Hengge et al. 1996, HIV wasting populations) | Hepatotoxic signal confirmed | High |
| 17-alpha alkylation is the structural basis of oral hepatotoxicity | Mechanistic/biochemical consensus; pharmacology textbooks | Accepted mechanism | High |
| Oxymetholone increases lean mass in HIV-associated wasting | Human RCT (Hengge et al., Strawford et al. 1999) | Positive effect confirmed | Moderate |
| Bypassing first pass reduces hepatic exposure meaningfully | Pharmacokinetic theory; no oxymetholone-specific human data | Plausible directional reduction | Low |
| Injectable oxymetholone is clinically safer than oral on the liver | No human comparative trial exists | Unproven | Very Low |
| Injectable oxymetholone produces superior anabolic outcomes | No human comparative trial exists | Unproven | Very Low |
| Gray-market injectable oxymetholone matches label concentration | Anecdotal; no systematic independent assay data available | Unreliable | Very Low |
How Does Anadrol Work and What Do the Specific Numbers Show?
Oxymetholone acts primarily as an agonist at the androgen receptor (AR). Unlike testosterone, it does not bind appreciably to sex hormone-binding globulin (SHBG), meaning a higher fraction circulates free. It also has documented estrogenic activity, which is unusual for a DHT derivative and contributes to fluid retention and gynecomastia risk. The mechanism behind this estrogenic effect is not fully characterized but is thought to involve direct estrogen receptor activity rather than aromatization.
In the landmark Hengge et al. trial (1996) in HIV-positive men, oxymetholone at 150 mg per day over 30 weeks produced mean lean body mass gains and was associated with liver enzyme elevations in a dose-dependent pattern. Strawford et al. (1999) in a randomized trial also demonstrated significant lean mass accrual with oxymetholone 100 mg per day combined with resistance training in HIV wasting, alongside documented ALT elevations.
Mechanistically, what the anabolic numbers do NOT prove: muscle mass gains in a catabolic disease state do not translate directly to gains in healthy individuals, and none of these trials used injectable oxymetholone.
Why Does 17-Alpha Alkylation Cause Liver Damage Regardless of Route?
This is the chemistry that justifies the injectable-is-safer claim and also explains why the claim is overstated.
The 17-alpha methyl group was added to oxymetholone specifically to resist hepatic first-pass metabolism that would otherwise rapidly inactivate it. The problem is that this same structural modification disrupts normal bile salt export pump (BSEP) function and multidrug resistance protein 2 (MRP2) transport in hepatocytes, impairing bile flow and causing cholestatic injury. This disruption occurs every time the oxymetholone molecule contacts a hepatocyte, whether it arrives via the portal vein after oral absorption or via systemic circulation after injection.
Oral dosing does produce higher peak portal vein concentrations, which means a larger initial hepatic exposure spike. Injection flattens that spike. This is why the injection route is plausible as partially hepatoprotective. However, the drug still reaches hepatic sinusoids through systemic circulation on subsequent passes, and the cumulative hepatic load over a cycle is driven more by total dose and duration than by Tmax alone. The reduction in peak portal concentration does not eliminate the cholestatic mechanism. No human data quantifies by how much, if any, this translates to reduced liver injury with oxymetholone specifically.
What Most Pages Get Wrong About Injectable Anadrol
This is the section competitor pages skip entirely.
No approved product exists. Every injectable oxymetholone product available in non-clinical settings is either compounded (with varying legality) or an unregulated gray-market substance. Unlike testosterone or nandrolone, which have long pharmaceutical injectable histories and established pharmacopeial standards, oxymetholone never advanced to an approved injectable form. There is no USP monograph for injectable oxymetholone solution. No regulatory agency has ever reviewed injectable oxymetholone safety data in a controlled submission.
Concentration is unverified. Third-party assay data on gray-market injectable oxymetholone is sparse and unsystematic. Mislabeling, underdosing, and contamination (including with other steroids or solvents) are documented problems in the broader unregulated AAS market. A product labeled "50 mg/mL oxymetholone in oil" carries no analytical guarantee.
Solvent risk is real. Oil-based injectable preparations require a carrier (commonly benzyl benzoate and benzyl alcohol as bacteriostat). At concentrations used for dense steroids, these solvents can cause injection-site reactions, and at high benzyl alcohol concentrations they carry their own toxicity concerns. This risk is absent from oral tablets.
The half-life argument is commonly reversed. Many sites claim injections last longer, implying less frequent dosing. This confuses absorption half-life (depot effect, which is real) with elimination half-life (which is the molecule's own, roughly 8 to 9 hours). You would still need frequent dosing to maintain stable blood levels unless the oil depot dramatically slows absorption, and for oxymetholone in oil, this has not been characterized in published pharmacokinetic studies.
Honest Head-to-Head: Injectable Oxymetholone vs Oral Oxymetholone vs Oxandrolone
| Factor | Injectable Oxymetholone | Oral Oxymetholone | Oral Oxandrolone |
|---|---|---|---|
| Regulatory approval | None anywhere | FDA-approved (Anadrol-50) | FDA-approved (Oxandrin) |
| Hepatotoxicity mechanism | 17-alpha alkylation (same molecule) | 17-alpha alkylation plus first-pass spike | 17-alpha alkylation, lower signal in trials |
| Peak portal concentration | Lower (bypassed on first pass) | Higher | Higher |
| Liver enzyme elevation in trials | No human data | Documented dose-dependent elevation | Lower elevation documented in comparative studies |
| Anabolic efficacy evidence | No human comparative trial | Multiple human trials (HIV wasting, anemia) | Multiple human trials (wasting, burns, osteoporosis) |
| Injection-site risk | Yes (solvent, sterility) | None | None |
| Supply reliability and purity | Unregulated, unverified | Pharmaceutical grade when sourced legitimately | Pharmaceutical grade when sourced legitimately |
| HPG axis suppression | Yes (same molecule) | Yes | Yes, generally considered less severe at clinical doses |
| Fluid retention | Yes | Yes | Notably lower |
| Where injectable LOSES | Regulatory status, purity assurance, injection risk, lack of evidence | N/A (reference) | N/A |
Honest verdict: Oxandrolone wins on safety profile in every domain where human evidence exists. Oral oxymetholone wins over injectable oxymetholone on regulatory status and supply reliability. The injectable form has no documented advantage that has been demonstrated in a human trial.
Half-Life, Depot Effects, and Plasma Curves Explained
Oxymetholone's elimination half-life is reported in pharmacological references as approximately 8 to 9 hours. This figure reflects the time for plasma concentration to fall by half after absorption is complete, and it is a property of how quickly the body metabolizes and excretes the molecule, not of how it was administered.
An oil-based injectable formulation can create a subcutaneous or intramuscular depot where drug is slowly released into circulation. This slows absorption (increases Tmax, lowers Cmax) and can smooth the plasma concentration curve. For some drugs, this is clinically meaningful (testosterone cypionate depot lasts days to weeks). For oxymetholone in oil, the depot duration has not been characterized in any published pharmacokinetic study. Whether it meaningfully extends the dosing interval beyond what is required by the 8 to 9 hour elimination half-life is speculative.
From a practical standpoint, stable plasma levels of any compound with an 8 to 9 hour half-life require dosing at least once daily, and many protocols use twice-daily dosing to reduce peak-to-trough variation. A moderate depot effect might reduce the need for split dosing but would not allow weekly injections the way long-ester testosterone does.
Operational and Label Literacy: How to Read What You Actually Have
If you are evaluating any oxymetholone product, oral or injectable, these are the questions to ask before trusting it:
For oral tablets (the only approved form):
- Is the NDC number traceable to an FDA-registered manufacturer? Anadrol-50 (oxymetholone 50 mg tablets) has a legitimate FDA listing. Verify at DailyMed or the FDA's NDC directory.
- Does the pill have a consistent imprint, color, and weight? Pharmaceutical tablets have tight manufacturing tolerances.
- Avoid any tablet claiming to be oxymetholone that lacks an identifiable manufacturer and NDC.
For any injectable product claiming to be oxymetholone:
- No FDA-approved reference product exists, so there is no pharmaceutical standard to compare against.
- Request a certificate of analysis (COA) with HPLC purity data from an independent third-party laboratory (not the seller's in-house lab).
- Check that the COA lists the compound by full IUPAC name or CAS number (CAS 434-07-1 for oxymetholone).
- Confirm the solvent system (carrier oil, benzyl benzoate percentage, benzyl alcohol percentage) is within ranges used in pharmaceutical injectables. Benzyl alcohol above 2 percent by volume is associated with toxicity concerns.
- Inspect for particulates, cloudiness, or color change. Oxymetholone in oil should be clear to slightly yellow and free of visible particles. Cloudiness may indicate contamination or precipitation.
- A degraded or counterfeit injectable may smell strongly of solvent, appear darker than expected, or have visible crystalline deposits.
Reconstitution does not apply here (oxymetholone injectables are pre-dissolved in oil, not lyophilized powders), but if you receive a powder claiming to be oxymetholone for self-compounding, the absence of sterile filtration equipment and aseptic technique creates serious infection risk. This is not a DIY process.
FAQ
Is injectable anadrol safer for the liver than oral anadrol?
The evidence does not confirm this. Oxymetholone's hepatotoxicity is driven by the molecule itself, not first-pass metabolism alone. Bypassing the liver on the first pass reduces peak portal concentrations, but systemic oxymetholone still reaches the liver. No controlled human trial has demonstrated a clinically meaningful difference in liver enzyme elevation between routes.
Does injectable anadrol have a different half-life than oral?
The oxymetholone molecule itself has a reported half-life of roughly 8 to 9 hours regardless of route. An oil-based injectable suspension can create a depot effect that slows absorption and smooths the plasma curve, but this reflects absorption kinetics, not a change in the drug's elimination half-life.
Is injectable oxymetholone a pharmaceutical product?
No approved injectable oxymetholone product exists in the United States or most regulated markets. The oral tablet (Anadrol-50) is the only FDA-approved form. Injectable versions circulating in research or gray markets are compounded or unregulated, carrying significant purity and dosing uncertainty.
What are the main risks shared by both injectable and oral anadrol?
Both routes deliver the same molecule with the same androgenic and estrogenic activity. Shared risks include hepatotoxicity, suppression of the hypothalamic-pituitary-gonadal axis, erythrocytosis, fluid retention, dyslipidemia, and virilization in women. Route does not eliminate these risks.
Does the injectable route improve muscle-building effects of anadrol?
There is no human RCT comparing anabolic outcomes between injectable and oral oxymetholone. Any claims that injections produce superior hypertrophy are based on pharmacokinetic theory, not direct evidence. Anabolic effect correlates with area under the curve exposure, which may not differ meaningfully between routes at equivalent doses.
What does anadrol do to liver enzymes specifically?
Clinical trials in patients with aplastic anemia and HIV-associated wasting showed that oxymetholone at 50 to 200 mg per day produces dose-dependent elevations in ALT and AST. Peliosis hepatis and cholestasis have also been documented in long-term case reports. These effects are attributed to the 17-alpha alkylation of the molecule.
How does oxymetholone compare to oxandrolone for safety?
Oxandrolone is consistently described in the medical literature as having a more favorable hepatic safety profile than oxymetholone, based on lower rates of liver enzyme elevation in comparable clinical populations. Both are 17-alpha alkylated, but oxymetholone carries a substantially higher hepatotoxicity signal in published trials.
Can you make injectable anadrol at home or buy it legally?
Oxymetholone is a Schedule III controlled substance in the United States. Compounding injectable oxymetholone without a prescription and appropriate licensure is illegal. Products sold online as injectable anadrol are unregulated, unverified for concentration, and may contain contaminants or incorrect active ingredients.
What is the typical clinical dose of oral oxymetholone?
The FDA-approved dosing range for oxymetholone tablets is 1 to 5 mg per kilogram of body weight per day. In practice, clinical trials for conditions like HIV-associated wasting most commonly used 100 mg or 150 mg per day. Bodybuilding doses in the literature frequently exceed the upper approved range.
Does injectable anadrol avoid androgenic side effects?
No. Oxymetholone is a potent androgen regardless of route. Androgenic activity is a property of the molecule and its metabolites, not of how it enters the body. Injectable administration does not meaningfully reduce androgenic side effects such as acne, alopecia, or virilization.
Is there any legitimate medical use for injectable anadrol?
No regulatory agency has approved an injectable oxymetholone product. The approved medical uses of oxymetholone (anemia from bone marrow failure, HIV wasting) are served by the oral tablet. Injectable use exists only in unregulated contexts.
Sources
- FDA. Anadrol-50 (oxymetholone) Prescribing Information. Alaven Pharmaceutical LLC. Available via DailyMed, National Library of Medicine.
- Hengge UR, Stocks K, Faulkner S, et al. Oxymetholone for the treatment of HIV-wasting: a double-blind, randomized, placebo-controlled study. HIV Med. 2003; describes the oxymetholone 150 mg/day dosing in HIV populations.
- Strawford A, Barbieri T, Van Loan M, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss. JAMA. 1999;281(14):1282-1290.
- Besa EC. Hematologic effects of androgens revisited: an alternative therapy in various hematologic conditions. Semin Hematol. 1994;31(2):134-145.
- Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004;38 Suppl 2:S44-48. (Context on cholestatic mechanisms of 17-alpha alkylated steroids.)
- Boelsterli UA, Lim PL. Mitochondrial abnormalities: a link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharmacol. 2007;220(1):92-107. (Mechanistic context on BSEP inhibition.)
- United States Drug Enforcement Administration. Controlled Substances Schedules. Schedule III: Anabolic Steroids. 21 U.S.C. 812.
- Llewellyn W. Anabolics, 10th edition. Molecular Nutrition LLC, 2010. (Pharmacokinetic background reference; not a peer-reviewed source but widely cited for oxymetholone half-life estimates.)